Cellectar BiosciencesCLRB
13F holders, Q4 2024 (December 31)30holders −5
5new positions
10sold out
$0.30avg. 13F price*
At the end of Q4 2024, 30 institutions reported holding Cellectar Biosciences Inc. (CLRB) in their 13F filings, down 5 from Q3 2024. 5 opened new positions and 10 sold out. The largest holders were Vanguard Group Inc. ($516K), ADAR1 Capital Management, LLC ($175K) and Squarepoint Ops LLC ($156K).
- Company
- Cellectar Biosciences Inc.
- CUSIP
- 15117F807
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $186K |
| Exits | 10 | $20.9M |
All 13F filers, Q3 2024 → Q4 2024: 1,354,739 shares bought and 10,233,674 shares sold, net −8,878,935 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 30 holders
| Vanguard Group Inc. | 0.00% | Add +0.0% | 1,727,001 | $516K |
| ADAR1 Capital Management, LLC | 0.04% | Reduce -42.7% | 585,261 | $175K |
| Squarepoint Ops LLC | 0.00% | New | 520,240 | $156K |
| UBS Group AG | 0.00% | Add +14498.3% | 376,199 | $112K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.4% | 350,885 | $105K |
| BlackRock, Inc. | 0.00% | Add +0.1% | 232,509 | $70K |
| Altium Capital Management LLC | 0.02% | No change | 215,000 | $64K |
| Bank of America Corp. | 0.00% | Add +25.3% | 206,783 | $62K |
| JPMorgan Chase & Co. | 0.00% | Add +687.3% | 182,403 | $55K |
| Morgan Stanley | 0.00% | Add +28.4% | 178,719 | $53K |
| State Street Corp. | 0.00% | Add +9.7% | 128,114 | $38K |
| Northern Trust Corp. | 0.00% | Add +27.6% | 77,988 | $23K |
| Two Sigma Investments, LP | 0.00% | New | 71,119 | $21K |
| Two Sigma Securities, LLC | 0.00% | Add +127.9% | 51,952 | $16K |
| XTX Topco Ltd | 0.00% | Reduce -11.6% | 46,876 | $14K |
| Goldman Sachs Group Inc. | 0.00% | Add +106.9% | 42,462 | $13K |
| Simplex Trading, LLC | 0.00% | Add +9486.6% | 40,743 | $12K |
| BNP Paribas Financial Markets | 0.00% | New | 16,815 | $5K |
| Sequoia Financial Advisors, LLC | 0.00% | Reduce -39.1% | 14,500 | $4K |
| Commonwealth Equity Services, LLC | 0.00% | New | 12,051 | $4K |
| Oppenheimer & Co. Inc. | 0.00% | No change | 12,500 | $4K |
| Osaic Holdings, Inc. | 0.00% | Reduce -4.4% | 2,721 | $816 |
| Group One Trading LLC | 0.00% | No change | 1,398 | $418 |
| Bfsg, LLC | 0.00% | No change | 1,000 | $299 |
| Citigroup Inc. | 0.00% | New | 660 | $197 |
| SBI Securities Co., Ltd. | 0.00% | — | 400 | $120 |
| US Bancorp \de | 0.00% | No change | 385 | $115 |
| EnRich Financial Partners LLC | 0.00% | No change | 102 | $30 |
| Harbour Investments, Inc. | 0.00% | No change | 40 | $12 |
| AllSquare Wealth Management LLC | 0.00% | No change | 18 | $5 |
"% of holder's portfolio" is CLRB's weight in each manager's 13F, not the share of Cellectar Biosciences Inc. the manager owns.